Biohaven Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value
Biohaven Ltd. (BHVN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value of $2.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue · last filed 2026-08-10
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-06-30 was $2.01M, a 1316.20% increase year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2026-03-31 was $91.00K, a 93.61% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-12-31 was $425.00K, a 95.35% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for the quarter ending 2025-09-30 was $130.00K, a 98.98% decline year-over-year.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2025 was $2.12M, a 93.73% decline from fiscal 2024.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2024 was $33.80M, a 335.80% increase from fiscal 2023.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2023 was $7.76M, a 61.48% decline from fiscal 2022.
- Biohaven Ltd. share-based compensation arrangement by share-based payment award, options, exercises in period, intrinsic value for fiscal 2022 was $20.14M.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $2.10M 10-Q · filed 2026-08-10 | $2.53M derived: sum of 3 quarters · filed 2026-08-10 | $2.66M derived: sum of 4 quarters · filed 2026-08-10 |
| 2026-03-31 | $91.00K 10-Q · filed 2026-05-04 | $516.00K derived: sum of 2 quarters · filed 2026-05-04 | $646.00K derived: sum of 3 quarters · filed 2026-05-04 | $788.00K derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-12-31 | $425.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $555.00K derived: sum of 2 quarters · filed 2026-03-02 | $697.00K derived: sum of 3 quarters · filed 2026-08-10 | $2.12M 10-K · filed 2026-03-02 |
| 2025-09-30 | $130.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $272.00K derived: sum of 2 quarters · filed 2026-08-10 | $1.70M 10-Q · filed 2025-11-10 | $10.83M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-06-30 | $142.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-10 | $1.57M 10-Q · filed 2026-08-10 | $10.70M derived: sum of 3 quarters · filed 2026-08-10 | $23.49M derived: sum of 4 quarters · filed 2026-08-10 |
| 2025-03-31 | $1.42M 10-Q · filed 2026-05-04 | $10.55M derived: sum of 2 quarters · filed 2026-05-04 | $23.34M derived: sum of 3 quarters · filed 2026-05-04 | |
| 2024-12-31 | $9.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $21.92M derived: sum of 2 quarters · filed 2026-03-02 | $33.80M 10-K · filed 2026-03-02 | |
| 2024-09-30 | $12.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $24.67M 10-Q · filed 2025-11-10 | ||
| 2024-06-30 | $11.88M 10-Q · filed 2025-08-11 | |||
| 2023-12-31 | $7.76M 10-K · filed 2026-03-02 | |||
| 2022-12-31 | $20.14M 10-K · filed 2025-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |